JP2021515806A5 - - Google Patents
Info
- Publication number
- JP2021515806A5 JP2021515806A5 JP2020568847A JP2020568847A JP2021515806A5 JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5 JP 2020568847 A JP2020568847 A JP 2020568847A JP 2020568847 A JP2020568847 A JP 2020568847A JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- antigen
- binding protein
- protein according
- triple
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637470P | 2018-03-02 | 2018-03-02 | |
| US62/637,470 | 2018-03-02 | ||
| PCT/EP2019/055207 WO2019166650A1 (en) | 2018-03-02 | 2019-03-01 | Trispecific antigen binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515806A JP2021515806A (ja) | 2021-06-24 |
| JP2021515806A5 true JP2021515806A5 (https=) | 2022-03-09 |
Family
ID=65802034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568847A Pending JP2021515806A (ja) | 2018-03-02 | 2019-03-01 | 三重特異性抗原結合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200062858A1 (https=) |
| EP (1) | EP3759146A1 (https=) |
| JP (1) | JP2021515806A (https=) |
| KR (1) | KR20210028140A (https=) |
| CN (1) | CN112119099A (https=) |
| AU (1) | AU2019228128A1 (https=) |
| CA (1) | CA3089230A1 (https=) |
| MX (1) | MX2020009116A (https=) |
| WO (1) | WO2019166650A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| JP2023501942A (ja) * | 2019-11-08 | 2023-01-20 | ナノテンパー・テクノロジーズ・ゲーエムベーハー | 溶液中の粒子の特徴付け |
| CA3164623A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| WO2022087211A1 (en) * | 2020-10-22 | 2022-04-28 | Janux Therapeutics, Inc. | Antibodies targeting her2 and cd3 and uses thereof |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| AU2022286960A1 (en) * | 2021-06-03 | 2024-01-18 | Harpoon Therapeutics, Inc. | Bcma targeting trispecific proteins and methods of use |
| KR20240067088A (ko) * | 2021-09-16 | 2024-05-16 | 지티 바이오파마, 인크. | 융합 단백질을 표적으로 하는 pd-l1 및 이의 사용 방법 |
| CN114371282B (zh) * | 2021-12-30 | 2025-07-11 | 上海药明生物技术有限公司 | 一种评估抗原沉默效应对抗体药效影响的方法及其应用 |
| AU2024317606A1 (en) * | 2023-07-29 | 2026-02-26 | Chimagen Biosciences, Ltd | Modified type e multi-specific antibodies |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| PT1049787E (pt) * | 1998-01-23 | 2005-04-29 | Vlaams Interuniv Inst Biotech | Derivados de anticorpos multipropositos |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| EP4245376A3 (en) * | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| HRP20191873T1 (hr) | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| WO2018028647A1 (en) | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| WO2017106453A1 (en) | 2015-12-17 | 2017-06-22 | University Of Maryland, Baltimore County | A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression |
| WO2017124002A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CA3020633A1 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| US11414491B2 (en) | 2016-05-18 | 2022-08-16 | Mayo Foundation For Medical Education And Research | Targeting PD-L1 on tumor cells |
| WO2017201493A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
| EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| US20190225702A1 (en) | 2016-10-14 | 2019-07-25 | Harpoon Therapeutics, Inc. | Innate immune cell trispecific binding proteins and methods of use |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| EP3645050A4 (en) * | 2017-06-25 | 2021-08-11 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
-
2019
- 2019-03-01 CA CA3089230A patent/CA3089230A1/en active Pending
- 2019-03-01 MX MX2020009116A patent/MX2020009116A/es unknown
- 2019-03-01 KR KR1020207028030A patent/KR20210028140A/ko not_active Ceased
- 2019-03-01 AU AU2019228128A patent/AU2019228128A1/en not_active Abandoned
- 2019-03-01 CN CN201980016065.6A patent/CN112119099A/zh active Pending
- 2019-03-01 JP JP2020568847A patent/JP2021515806A/ja active Pending
- 2019-03-01 EP EP19711257.6A patent/EP3759146A1/en not_active Withdrawn
- 2019-03-01 WO PCT/EP2019/055207 patent/WO2019166650A1/en not_active Ceased
- 2019-08-05 US US16/532,295 patent/US20200062858A1/en not_active Abandoned
- 2019-10-04 US US16/593,704 patent/US20200024358A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515806A5 (https=) | ||
| JP2020521448A5 (https=) | ||
| JP2024099850A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| JP2020522473A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2013545455A5 (https=) | ||
| JP2020063262A5 (https=) | ||
| JP2021533161A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| JP2023504016A5 (https=) | ||
| JP2017504577A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2020114210A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| JP2014518615A5 (https=) | ||
| JP2021511811A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| JP2023507729A5 (https=) | ||
| JP2020522474A5 (https=) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела |